Cytotoxic T-lymphocyte associated protein 4 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cytotoxic T-lymphocyte associated protein 4" in English language version.

refsWebsite

Global rank English rank

54nih.gov

4^th place

34doi.org

2^nd place

9harvard.edu

18^th place

17^th place

7semanticscholar.org

11^th place

8^th place

2ensembl.org

1,626^th place

1,007^th place

1jstor.org

26^th place

20^th place

1cell.com

2,814^th place

6,533^rd place

1nobelprize.org

301^st place

478^th place

cell.com

Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (November 1995). "Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4" (PDF). Immunity. 3 (5): 541–7. doi:10.1016/1074-7613(95)90125-6. PMID 7584144.

doi.org

Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet. Oncology. 18 (12): e731 – e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P (1987). "A new member of the immunoglobulin superfamily--CTLA-4". Nature. 328 (6127): 267–70. Bibcode:1987Natur.328..267B. doi:10.1038/328267a0. PMID 3496540. S2CID 4316396.
Dariavach P, Mattéi MG, Golstein P, Lefranc MP (December 1988). "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains". European Journal of Immunology. 18 (12): 1901–5. doi:10.1002/eji.1830181206. PMID 3220103. S2CID 34071559.
Bashyam, Hema (June 2007). "CTLA-4: From conflict to clinic". J Exp Med. 204 (6): 1243. doi:10.1084/jem.2046fta. PMC 2118622. PMID 17632849.
Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. (November 1995). "Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4". Science. 270 (5238): 985–8. Bibcode:1995Sci...270..985W. doi:10.1126/science.270.5238.985. JSTOR 2888113. PMID 7481803. S2CID 45993765.
Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (November 1995). "Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4" (PDF). Immunity. 3 (5): 541–7. doi:10.1016/1074-7613(95)90125-6. PMID 7584144.
Pardoll DM (December 2012). "Immunology beats cancer: a blueprint for successful translation". Nature Immunology. 13 (12): 1129–32. doi:10.1038/ni.2392. PMC 4659410. PMID 23160205.
Krummel MF, Allison JP (August 1995). "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation". The Journal of Experimental Medicine. 182 (2): 459–65. doi:10.1084/jem.182.2.459. PMC 2192127. PMID 7543139.
Walunas TL, Bakker CY, Bluestone JA (June 1996). "CTLA-4 ligation blocks CD28-dependent T cell activation". The Journal of Experimental Medicine. 183 (6): 2541–50. doi:10.1084/jem.183.6.2541. PMC 2192609. PMID 8676075.
Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. (August 1994). "CTLA-4 can function as a negative regulator of T cell activation". Immunity. 1 (5): 405–13. doi:10.1016/1074-7613(94)90071-x. PMID 7882171.
Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP (April 1992). "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones". Nature. 356 (6370): 607–9. Bibcode:1992Natur.356..607H. doi:10.1038/356607a0. PMID 1313950. S2CID 4333730.
Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, Bonnefoy JY, Delneste Y (November 1999). "A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells". European Journal of Immunology. 29 (11): 3596–602. doi:10.1002/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y. PMID 10556814.
Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, et al. (December 1998). "Molecular basis of T cell inactivation by CTLA-4". Science. 282 (5397): 2263–6. Bibcode:1998Sci...282.2263L. doi:10.1126/science.282.5397.2263. PMID 9856951.
Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. (April 2011). "Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4". Science. 332 (6029): 600–3. Bibcode:2011Sci...332..600Q. doi:10.1126/science.1202947. PMC 3198051. PMID 21474713.
Chen J, Ganguly A, Mucsi AD, Meng J, Yan J, Detampel P, et al. (February 2017). "Strong adhesion by regulatory T cells induces dendritic cell cytoskeletal polarization and contact-dependent lethargy". The Journal of Experimental Medicine. 214 (2): 327–338. doi:10.1084/jem.20160620. PMC 5294852. PMID 28082358.
Knieke K, Lingel H, Chamaon K, Brunner-Weinzierl MC (2012). "Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation". PLOS ONE. 7 (3): e31391. Bibcode:2012PLoSO...731391K. doi:10.1371/journal.pone.0031391. PMC 3295805. PMID 22412835.
Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, et al. (September 2006). "Reversal of the TCR stop signal by CTLA-4". Science. 313 (5795): 1972–5. Bibcode:2006Sci...313.1972S. doi:10.1126/science.1131078. PMID 16931720. S2CID 27123046.
Rudd CE, Taylor A, Schneider H (May 2009). "CD28 and CTLA-4 coreceptor expression and signal transduction". Immunological Reviews. 229 (1): 12–26. doi:10.1111/j.1600-065X.2009.00770.x. PMC 4186963. PMID 19426212.
Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, et al. (November 2009). "Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal". Nature Immunology. 10 (11): 1185–92. doi:10.1038/ni.1790. PMC 2778301. PMID 19783989.
Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. (August 2013). "Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma". The Journal of Experimental Medicine. 210 (9): 1695–710. doi:10.1084/jem.20130579. PMC 3754863. PMID 23897981.
Westra HJ, Martínez-Bonet M, Onengut-Gumuscu S, Lee A, Luo Y, Teslovich N, et al. (October 2018). "Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes". Nature Genetics. 50 (10): 1366–1374. doi:10.1038/s41588-018-0216-7. PMC 6364548. PMID 30224649.
Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. (September 2014). "Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4". Science. 345 (6204): 1623–1627. Bibcode:2014Sci...345.1623K. doi:10.1126/science.1255904. PMC 4371526. PMID 25213377.
Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. (December 2014). "Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations". Nature Medicine. 20 (12): 1410–1416. doi:10.1038/nm.3746. PMC 4668597. PMID 25329329.
Kaninia S, Grammatikos A, Urankar K, Renowden SA, Patel NK, Gompels MM, Rice CM (August 2021). "CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant". Multiple Sclerosis. 27 (9): 1464–1467. doi:10.1177/1352458520963896. PMC 8358566. PMID 34097529.
Grammatikos A, Johnston S, Rice CM, Gompels M (August 2021). "A Family with a Novel CTLA4 Haploinsufficiency Mutation and Neurological Symptoms". Journal of Clinical Immunology. 41 (6): 1411–1416. doi:10.1007/s10875-021-01027-1. PMC 8310858. PMID 33956248.
Zeissig S, Petersen BS, Tomczak M, Melum E, Huc-Claustre E, Dougan SK, et al. (December 2015). "Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4". Gut. 64 (12): 1889–97. doi:10.1136/gutjnl-2014-308541. PMC 4512923. PMID 25367873.
Lee S, Moon JS, Lee CR, Kim HE, Baek SM, Hwang S, et al. (January 2016). "Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4". The Journal of Allergy and Clinical Immunology. 137 (1): 327–330. doi:10.1016/j.jaci.2015.08.036. PMID 26478010.
Westhovens R, et al. (2004). "Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment". Arthritis Research & Therapy. 6 (Suppl 1): 86. doi:10.1186/ar1128. PMC 2833769.
Pardoll DM (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12 (4): 252–64. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.
Follows ER, McPheat JC, Minshull C, Moore NC, Pauptit RA, Rowsell S, et al. (October 2001). "Study of the interaction of the medium chain mu 2 subunit of the clathrin-associated adapter protein complex 2 with cytotoxic T-lymphocyte antigen 4 and CD28". The Biochemical Journal. 359 (Pt 2): 427–34. doi:10.1042/0264-6021:3590427. PMC 1222163. PMID 11583591.
Chuang E, Alegre ML, Duckett CS, Noel PJ, Vander Heiden MG, Thompson CB (July 1997). "Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression". Journal of Immunology. 159 (1): 144–51. doi:10.4049/jimmunol.159.1.144. PMID 9200449. S2CID 25449038.
Peach RJ, Bajorath J, Naemura J, Leytze G, Greene J, Aruffo A, Linsley PS (September 1995). "Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28". The Journal of Biological Chemistry. 270 (36): 21181–7. doi:10.1074/jbc.270.36.21181. PMID 7545666.
Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, et al. (March 2001). "Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses". Nature. 410 (6828): 608–11. Bibcode:2001Natur.410..608S. doi:10.1038/35069118. PMID 11279502. S2CID 4329622.
Baroja ML, Vijayakrishnan L, Bettelli E, Darlington PJ, Chau TA, Ling V, et al. (May 2002). "Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A". Journal of Immunology. 168 (10): 5070–8. doi:10.4049/jimmunol.168.10.5070. PMID 11994459.

ensembl.org

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000163599 – Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000026011 – Ensembl, May 2017

harvard.edu

ui.adsabs.harvard.edu

Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P (1987). "A new member of the immunoglobulin superfamily--CTLA-4". Nature. 328 (6127): 267–70. Bibcode:1987Natur.328..267B. doi:10.1038/328267a0. PMID 3496540. S2CID 4316396.
Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. (November 1995). "Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4". Science. 270 (5238): 985–8. Bibcode:1995Sci...270..985W. doi:10.1126/science.270.5238.985. JSTOR 2888113. PMID 7481803. S2CID 45993765.
Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP (April 1992). "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones". Nature. 356 (6370): 607–9. Bibcode:1992Natur.356..607H. doi:10.1038/356607a0. PMID 1313950. S2CID 4333730.
Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, et al. (December 1998). "Molecular basis of T cell inactivation by CTLA-4". Science. 282 (5397): 2263–6. Bibcode:1998Sci...282.2263L. doi:10.1126/science.282.5397.2263. PMID 9856951.
Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. (April 2011). "Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4". Science. 332 (6029): 600–3. Bibcode:2011Sci...332..600Q. doi:10.1126/science.1202947. PMC 3198051. PMID 21474713.
Knieke K, Lingel H, Chamaon K, Brunner-Weinzierl MC (2012). "Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation". PLOS ONE. 7 (3): e31391. Bibcode:2012PLoSO...731391K. doi:10.1371/journal.pone.0031391. PMC 3295805. PMID 22412835.
Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, et al. (September 2006). "Reversal of the TCR stop signal by CTLA-4". Science. 313 (5795): 1972–5. Bibcode:2006Sci...313.1972S. doi:10.1126/science.1131078. PMID 16931720. S2CID 27123046.
Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. (September 2014). "Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4". Science. 345 (6204): 1623–1627. Bibcode:2014Sci...345.1623K. doi:10.1126/science.1255904. PMC 4371526. PMID 25213377.
Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, et al. (March 2001). "Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses". Nature. 410 (6828): 608–11. Bibcode:2001Natur.410..608S. doi:10.1038/35069118. PMID 11279502. S2CID 4329622.

jstor.org

Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. (November 1995). "Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4". Science. 270 (5238): 985–8. Bibcode:1995Sci...270..985W. doi:10.1126/science.270.5238.985. JSTOR 2888113. PMID 7481803. S2CID 45993765.

nih.gov

pubmed.ncbi.nlm.nih.gov

Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet. Oncology. 18 (12): e731 – e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P (1987). "A new member of the immunoglobulin superfamily--CTLA-4". Nature. 328 (6127): 267–70. Bibcode:1987Natur.328..267B. doi:10.1038/328267a0. PMID 3496540. S2CID 4316396.
Dariavach P, Mattéi MG, Golstein P, Lefranc MP (December 1988). "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains". European Journal of Immunology. 18 (12): 1901–5. doi:10.1002/eji.1830181206. PMID 3220103. S2CID 34071559.
Bashyam, Hema (June 2007). "CTLA-4: From conflict to clinic". J Exp Med. 204 (6): 1243. doi:10.1084/jem.2046fta. PMC 2118622. PMID 17632849.
Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. (November 1995). "Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4". Science. 270 (5238): 985–8. Bibcode:1995Sci...270..985W. doi:10.1126/science.270.5238.985. JSTOR 2888113. PMID 7481803. S2CID 45993765.
Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (November 1995). "Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4" (PDF). Immunity. 3 (5): 541–7. doi:10.1016/1074-7613(95)90125-6. PMID 7584144.
Pardoll DM (December 2012). "Immunology beats cancer: a blueprint for successful translation". Nature Immunology. 13 (12): 1129–32. doi:10.1038/ni.2392. PMC 4659410. PMID 23160205.
Krummel MF, Allison JP (August 1995). "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation". The Journal of Experimental Medicine. 182 (2): 459–65. doi:10.1084/jem.182.2.459. PMC 2192127. PMID 7543139.
Walunas TL, Bakker CY, Bluestone JA (June 1996). "CTLA-4 ligation blocks CD28-dependent T cell activation". The Journal of Experimental Medicine. 183 (6): 2541–50. doi:10.1084/jem.183.6.2541. PMC 2192609. PMID 8676075.
Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. (August 1994). "CTLA-4 can function as a negative regulator of T cell activation". Immunity. 1 (5): 405–13. doi:10.1016/1074-7613(94)90071-x. PMID 7882171.
Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP (April 1992). "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones". Nature. 356 (6370): 607–9. Bibcode:1992Natur.356..607H. doi:10.1038/356607a0. PMID 1313950. S2CID 4333730.
Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, Bonnefoy JY, Delneste Y (November 1999). "A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells". European Journal of Immunology. 29 (11): 3596–602. doi:10.1002/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y. PMID 10556814.
Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, et al. (December 1998). "Molecular basis of T cell inactivation by CTLA-4". Science. 282 (5397): 2263–6. Bibcode:1998Sci...282.2263L. doi:10.1126/science.282.5397.2263. PMID 9856951.
Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. (April 2011). "Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4". Science. 332 (6029): 600–3. Bibcode:2011Sci...332..600Q. doi:10.1126/science.1202947. PMC 3198051. PMID 21474713.
Chen J, Ganguly A, Mucsi AD, Meng J, Yan J, Detampel P, et al. (February 2017). "Strong adhesion by regulatory T cells induces dendritic cell cytoskeletal polarization and contact-dependent lethargy". The Journal of Experimental Medicine. 214 (2): 327–338. doi:10.1084/jem.20160620. PMC 5294852. PMID 28082358.
Knieke K, Lingel H, Chamaon K, Brunner-Weinzierl MC (2012). "Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation". PLOS ONE. 7 (3): e31391. Bibcode:2012PLoSO...731391K. doi:10.1371/journal.pone.0031391. PMC 3295805. PMID 22412835.
Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, et al. (September 2006). "Reversal of the TCR stop signal by CTLA-4". Science. 313 (5795): 1972–5. Bibcode:2006Sci...313.1972S. doi:10.1126/science.1131078. PMID 16931720. S2CID 27123046.
Rudd CE, Taylor A, Schneider H (May 2009). "CD28 and CTLA-4 coreceptor expression and signal transduction". Immunological Reviews. 229 (1): 12–26. doi:10.1111/j.1600-065X.2009.00770.x. PMC 4186963. PMID 19426212.
Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, et al. (November 2009). "Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal". Nature Immunology. 10 (11): 1185–92. doi:10.1038/ni.1790. PMC 2778301. PMID 19783989.
Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. (August 2013). "Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma". The Journal of Experimental Medicine. 210 (9): 1695–710. doi:10.1084/jem.20130579. PMC 3754863. PMID 23897981.
Westra HJ, Martínez-Bonet M, Onengut-Gumuscu S, Lee A, Luo Y, Teslovich N, et al. (October 2018). "Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes". Nature Genetics. 50 (10): 1366–1374. doi:10.1038/s41588-018-0216-7. PMC 6364548. PMID 30224649.
Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. (September 2014). "Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4". Science. 345 (6204): 1623–1627. Bibcode:2014Sci...345.1623K. doi:10.1126/science.1255904. PMC 4371526. PMID 25213377.
Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. (December 2014). "Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations". Nature Medicine. 20 (12): 1410–1416. doi:10.1038/nm.3746. PMC 4668597. PMID 25329329.
Kaninia S, Grammatikos A, Urankar K, Renowden SA, Patel NK, Gompels MM, Rice CM (August 2021). "CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant". Multiple Sclerosis. 27 (9): 1464–1467. doi:10.1177/1352458520963896. PMC 8358566. PMID 34097529.
Grammatikos A, Johnston S, Rice CM, Gompels M (August 2021). "A Family with a Novel CTLA4 Haploinsufficiency Mutation and Neurological Symptoms". Journal of Clinical Immunology. 41 (6): 1411–1416. doi:10.1007/s10875-021-01027-1. PMC 8310858. PMID 33956248.
Zeissig S, Petersen BS, Tomczak M, Melum E, Huc-Claustre E, Dougan SK, et al. (December 2015). "Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4". Gut. 64 (12): 1889–97. doi:10.1136/gutjnl-2014-308541. PMC 4512923. PMID 25367873.
Lee S, Moon JS, Lee CR, Kim HE, Baek SM, Hwang S, et al. (January 2016). "Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4". The Journal of Allergy and Clinical Immunology. 137 (1): 327–330. doi:10.1016/j.jaci.2015.08.036. PMID 26478010.
Pardoll DM (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12 (4): 252–64. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.
Follows ER, McPheat JC, Minshull C, Moore NC, Pauptit RA, Rowsell S, et al. (October 2001). "Study of the interaction of the medium chain mu 2 subunit of the clathrin-associated adapter protein complex 2 with cytotoxic T-lymphocyte antigen 4 and CD28". The Biochemical Journal. 359 (Pt 2): 427–34. doi:10.1042/0264-6021:3590427. PMC 1222163. PMID 11583591.
Chuang E, Alegre ML, Duckett CS, Noel PJ, Vander Heiden MG, Thompson CB (July 1997). "Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression". Journal of Immunology. 159 (1): 144–51. doi:10.4049/jimmunol.159.1.144. PMID 9200449. S2CID 25449038.
Peach RJ, Bajorath J, Naemura J, Leytze G, Greene J, Aruffo A, Linsley PS (September 1995). "Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28". The Journal of Biological Chemistry. 270 (36): 21181–7. doi:10.1074/jbc.270.36.21181. PMID 7545666.
Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, et al. (March 2001). "Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses". Nature. 410 (6828): 608–11. Bibcode:2001Natur.410..608S. doi:10.1038/35069118. PMID 11279502. S2CID 4329622.
Baroja ML, Vijayakrishnan L, Bettelli E, Darlington PJ, Chau TA, Ling V, et al. (May 2002). "Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A". Journal of Immunology. 168 (10): 5070–8. doi:10.4049/jimmunol.168.10.5070. PMID 11994459.

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Bashyam, Hema (June 2007). "CTLA-4: From conflict to clinic". J Exp Med. 204 (6): 1243. doi:10.1084/jem.2046fta. PMC 2118622. PMID 17632849.
Pardoll DM (December 2012). "Immunology beats cancer: a blueprint for successful translation". Nature Immunology. 13 (12): 1129–32. doi:10.1038/ni.2392. PMC 4659410. PMID 23160205.
Krummel MF, Allison JP (August 1995). "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation". The Journal of Experimental Medicine. 182 (2): 459–65. doi:10.1084/jem.182.2.459. PMC 2192127. PMID 7543139.
Walunas TL, Bakker CY, Bluestone JA (June 1996). "CTLA-4 ligation blocks CD28-dependent T cell activation". The Journal of Experimental Medicine. 183 (6): 2541–50. doi:10.1084/jem.183.6.2541. PMC 2192609. PMID 8676075.
Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. (April 2011). "Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4". Science. 332 (6029): 600–3. Bibcode:2011Sci...332..600Q. doi:10.1126/science.1202947. PMC 3198051. PMID 21474713.
Chen J, Ganguly A, Mucsi AD, Meng J, Yan J, Detampel P, et al. (February 2017). "Strong adhesion by regulatory T cells induces dendritic cell cytoskeletal polarization and contact-dependent lethargy". The Journal of Experimental Medicine. 214 (2): 327–338. doi:10.1084/jem.20160620. PMC 5294852. PMID 28082358.
Knieke K, Lingel H, Chamaon K, Brunner-Weinzierl MC (2012). "Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation". PLOS ONE. 7 (3): e31391. Bibcode:2012PLoSO...731391K. doi:10.1371/journal.pone.0031391. PMC 3295805. PMID 22412835.
Rudd CE, Taylor A, Schneider H (May 2009). "CD28 and CTLA-4 coreceptor expression and signal transduction". Immunological Reviews. 229 (1): 12–26. doi:10.1111/j.1600-065X.2009.00770.x. PMC 4186963. PMID 19426212.
Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, et al. (November 2009). "Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal". Nature Immunology. 10 (11): 1185–92. doi:10.1038/ni.1790. PMC 2778301. PMID 19783989.
Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. (August 2013). "Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma". The Journal of Experimental Medicine. 210 (9): 1695–710. doi:10.1084/jem.20130579. PMC 3754863. PMID 23897981.
Westra HJ, Martínez-Bonet M, Onengut-Gumuscu S, Lee A, Luo Y, Teslovich N, et al. (October 2018). "Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes". Nature Genetics. 50 (10): 1366–1374. doi:10.1038/s41588-018-0216-7. PMC 6364548. PMID 30224649.
Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. (September 2014). "Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4". Science. 345 (6204): 1623–1627. Bibcode:2014Sci...345.1623K. doi:10.1126/science.1255904. PMC 4371526. PMID 25213377.
Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. (December 2014). "Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations". Nature Medicine. 20 (12): 1410–1416. doi:10.1038/nm.3746. PMC 4668597. PMID 25329329.
Kaninia S, Grammatikos A, Urankar K, Renowden SA, Patel NK, Gompels MM, Rice CM (August 2021). "CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant". Multiple Sclerosis. 27 (9): 1464–1467. doi:10.1177/1352458520963896. PMC 8358566. PMID 34097529.
Grammatikos A, Johnston S, Rice CM, Gompels M (August 2021). "A Family with a Novel CTLA4 Haploinsufficiency Mutation and Neurological Symptoms". Journal of Clinical Immunology. 41 (6): 1411–1416. doi:10.1007/s10875-021-01027-1. PMC 8310858. PMID 33956248.
Zeissig S, Petersen BS, Tomczak M, Melum E, Huc-Claustre E, Dougan SK, et al. (December 2015). "Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4". Gut. 64 (12): 1889–97. doi:10.1136/gutjnl-2014-308541. PMC 4512923. PMID 25367873.
Westhovens R, et al. (2004). "Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment". Arthritis Research & Therapy. 6 (Suppl 1): 86. doi:10.1186/ar1128. PMC 2833769.
Pardoll DM (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12 (4): 252–64. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.
Follows ER, McPheat JC, Minshull C, Moore NC, Pauptit RA, Rowsell S, et al. (October 2001). "Study of the interaction of the medium chain mu 2 subunit of the clathrin-associated adapter protein complex 2 with cytotoxic T-lymphocyte antigen 4 and CD28". The Biochemical Journal. 359 (Pt 2): 427–34. doi:10.1042/0264-6021:3590427. PMC 1222163. PMID 11583591.

nobelprize.org

"The Nobel Prize in Physiology or Medicine 2018". NobelPrize.org. Retrieved 3 July 2023.

semanticscholar.org

api.semanticscholar.org

Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P (1987). "A new member of the immunoglobulin superfamily--CTLA-4". Nature. 328 (6127): 267–70. Bibcode:1987Natur.328..267B. doi:10.1038/328267a0. PMID 3496540. S2CID 4316396.
Dariavach P, Mattéi MG, Golstein P, Lefranc MP (December 1988). "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains". European Journal of Immunology. 18 (12): 1901–5. doi:10.1002/eji.1830181206. PMID 3220103. S2CID 34071559.
Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. (November 1995). "Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4". Science. 270 (5238): 985–8. Bibcode:1995Sci...270..985W. doi:10.1126/science.270.5238.985. JSTOR 2888113. PMID 7481803. S2CID 45993765.
Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP (April 1992). "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones". Nature. 356 (6370): 607–9. Bibcode:1992Natur.356..607H. doi:10.1038/356607a0. PMID 1313950. S2CID 4333730.
Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, et al. (September 2006). "Reversal of the TCR stop signal by CTLA-4". Science. 313 (5795): 1972–5. Bibcode:2006Sci...313.1972S. doi:10.1126/science.1131078. PMID 16931720. S2CID 27123046.
Chuang E, Alegre ML, Duckett CS, Noel PJ, Vander Heiden MG, Thompson CB (July 1997). "Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression". Journal of Immunology. 159 (1): 144–51. doi:10.4049/jimmunol.159.1.144. PMID 9200449. S2CID 25449038.
Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, et al. (March 2001). "Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses". Nature. 410 (6828): 608–11. Bibcode:2001Natur.410..608S. doi:10.1038/35069118. PMID 11279502. S2CID 4329622.